{"preliminary_commentary":{"by_channel":{"x_thread":11,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04559607\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["camrelizumab","rivoceranib"]],"indication":"unresectable hepatocellular carcinoma","name":"CARES-005","nct_id":"NCT04559607","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cares-005-nct04559607. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Camrelizumab (iv. infusion of 200 mg); Apatinib (po. administration of 250 mg); TACE","label":"Experimental group: TACE+Camrelizumab+Apatinib","type":"EXPERIMENTAL"},{"description":"TACE","label":"Control group: TACE","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-01-31","type":"ESTIMATED"},"conditions":["Hepatocellular Carcinoma"],"enrollment":{"count":188,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Camrelizumab","otherNames":[],"type":"DRUG"},{"name":"TACE","otherNames":[],"type":"DEVICE"},{"name":"Apatinib","otherNames":[],"type":"DRUG"}],"last_update":"2023-12-18","lead_sponsor":"Zhongda Hospital","official_title":"TACE Combined With Camrelizumab and Apatinib Versus TACE in Intermediate and Advanced Hepatocelluar Carcinoma: a Randomized, Open-label, Multi-center Clinical Trials","overall_status":"UNKNOWN","phases":["NA"],"primary_completion_date":{"date":"2024-08-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free survival (PFS) by investigator","timeFrame":"Up to ~2 years"}],"references":[{"citation":"Zhu HD, Fan WJ, Zhao C, Wang S, Li YL, Jin ZC, Zhang ZW, Guo JH, Cheng HT, Zhang Q, Lu J, Zeng YY, Lv WF, Xu H, Shao HB, Xu WG, Zhao XY, Gu SZ, Lin HL, Zheng WH, Piao LZ, Song YS, Zhao JB, Wang YC, Hou ZG, Sun Y, Guan N, Huang M, Yang WZ, Ji JS, Teng GJ. Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial. J Clin Oncol. 2026 Apr 10;44(11):959-969. doi: 10.1200/JCO-25-01796. Epub 2026 Feb 24.","pmid":"41734362","type":"DERIVED"}],"start_date":{"date":"2020-09-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma","url":"https://clinicaltrials.gov/study/NCT04559607"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cares-005-nct04559607"}